Articles On Dimerix (ASX:DXB)

Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne. In this episode Tim chats with CEO and MD of Dimerix, Nina Webster, and CEO of Pharmaxis, Gary Phillips. Dimerix...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

A Larger Pipeline Dimerix have diversified their drug pipeline by discovering DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). What is COPD? COPD is the fourth-leading cause of death in the world and although treatments exist to im...

Special Report: The inaugural Biotech Luncheon in Perth launched with a bang, with more than 150 guests attending the event last week. Hosted by industry entrepreneur Brian Leedman, the luncheon was established to raise awareness of, and bu...

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has announced plans to target the development of what it calls “an important new discovery” in the treatment of chronic obstructive pulmonary disease (COPD). The DMX-700 drug was i...

When it comes to the listed biotech space, getting the communication right is critical. For starters, it’s a sector geared around medical breakthroughs  usually based highly complex science. And for investors and market analysts, the outcom...

The WA investment community will turn its attention to healthcare next Thursday, when the annual Biotech Lunch takes place in Perth. Hosted by industry entrepreneur Brian Leedman, the luncheon will provide a forum for brokers and investors...

Dimerix Limited (ASX: DXB) Clinical-stage biopharmaceutical company, Dimerix Limited (ASX: DXB) is engaged in developing new therapies for the unmet requirements of the medicine market all over the world. On 26 June 2019, Dimerix announced...